<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03832179</url>
  </required_header>
  <id_info>
    <org_study_id>STAMP</org_study_id>
    <nct_id>NCT03832179</nct_id>
  </id_info>
  <brief_title>Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification</brief_title>
  <acronym>STAMP</acronym>
  <official_title>Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bay Area Retina Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bay Area Retina Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy of antecedent intravitreal
      anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery
      related macular edema in patients with pre-existing diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with pre-existing diabetic macular edema, anti-vascular endothelial growth factor
      therapy (Bevacizumab, ranibizumab, or aflibercept) will be compared to Ozurdex therapy
      administered 1 week prior to phacoemulsification cataract extraction. Spectral domain optical
      coherence tomography and visual acuity will be acquired at 1 week, 1 month, 2 months, and 3
      months following cataract surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two parallel groups, one group receiving anti-vascular endothelial growth factor and the other group receiving Ozurdex.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of central foveal thickness outcomes of anti-vascular endothelial growth factor vs. Ozurdex therapy</measure>
    <time_frame>3 months after cataract surgery</time_frame>
    <description>Central foveal thickness will be measured in microns by spectral domain optical coherence tomography (Heidelberg) and compared to baseline at post-operative week 1, postoperative month 1, postoperative month 2, and postoperative month 3 for both anti-vascular endothelial growth factor and Ozurdex groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity outcomes of anti-vascular endothelial growth factor vs. Ozurdex therapy</measure>
    <time_frame>3 months after cataract surgery</time_frame>
    <description>Snellen visual acuity will be measured and converted into logMAR and compared to baseline at post-operative week 1, postoperative month 1, postoperative month 2, and postoperative month 3 for both anti-vascular endothelial growth factor and Ozurdex groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Anti-vascular endothelial growth factor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Bevacizumab, Ranibizumab, or Aflibercept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal Ozurdex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab</description>
    <arm_group_label>Anti-vascular endothelial growth factor</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab</description>
    <arm_group_label>Anti-vascular endothelial growth factor</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Aflibercept</description>
    <arm_group_label>Anti-vascular endothelial growth factor</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <description>Ozurdex</description>
    <arm_group_label>Ozurdex</arm_group_label>
    <other_name>Dexamethasone implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of age

          -  Gender- All

          -  Race- All

          -  Diagnosis of Diabetes (Type 1 or 2) with a concomitant diagnosis of diabetic macular
             edema as demonstrated on spectral domain optical coherence tomography (Heidelberg
             Spectralis)

          -  &gt;250 microns central foveal thickness

          -  Able and willing to provide informed consent

        Exclusion Criteria:

          -  Significant renal disease

          -  A condition that in the opinion of the investigator would preclude participation

          -  Participation in another investigational trial within 30 days of randomization

          -  Application of focal macular laser within 120 days of enrollment

          -  Administration of Iluvien implant within 3 years of enrollment

          -  Administration of intravitreal triamcinolone within 3 months of enrollment

          -  Administration of any anti-vascular endothelial growth factor agent within 30 days of
             enrollment

          -  Known hypersensitivity to any of the investigational products

          -  Blood pressure &gt;180/110

          -  Women who are pregnant, lactating, or intend to become pregnant within 1 year of
             randomization

          -  Vulnerable populations- including but not limited to wards of the state, cognitively
             impaired individuals, prisoners, institutionalized individuals

          -  Individual is planning on moving within 6 months of study enrollment

          -  Macular edema secondary to cause other than diabetic macular edema

          -  Ocular condition that, in the opinion of the investigators, may affect course of
             macular edema during course of study (vein occlusion, uveitis, etc.)

          -  Evidence of ocular infections

          -  Evidence of uncontrolled glaucoma

          -  Known hypersensitivity to any components of bevacizumab, ranibizumab, aflibercept, or
             Ozurdex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caesar Luo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caesar Luo, MD</last_name>
    <phone>9259436800</phone>
    <email>cluo@bayarearetina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Farhan Ahmed</last_name>
    <phone>9259436800</phone>
    <email>fahmed@bayarearetina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhan Ahmed</last_name>
      <phone>925-943-6800</phone>
      <email>fahmed@bayarearetina.com</email>
    </contact>
    <contact_backup>
      <last_name>Caesar Luo, MD</last_name>
      <phone>9259436800</phone>
      <email>cluo@bayarearetina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Roger Goldberg, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tushar Ranchod, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Subhransu Ray, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Ting, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stewart Daniels, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig Leong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rauen PI, Ribeiro JA, Almeida FP, Scott IU, Messias A, Jorge R. Intravitreal injection of ranibizumab during cataract surgery in patients with diabetic macular edema. Retina. 2012 Oct;32(9):1799-803.</citation>
    <PMID>22495327</PMID>
  </reference>
  <reference>
    <citation>Furino C, Boscia F, Niro A, Giancipoli E, Grassi MO, D'amico Ricci G, Blasetti F, Reibaldi M, Alessio G. Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema. J Ophthalmol. 2017;2017:4896036. doi: 10.1155/2017/4896036. Epub 2017 Aug 13.</citation>
    <PMID>28884024</PMID>
  </reference>
  <reference>
    <citation>Calvo P, Ferreras A, Al Adel F, Dangboon W, Brent MH. EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY. Retina. 2018 Mar;38(3):490-496. doi: 10.1097/IAE.0000000000001552.</citation>
    <PMID>28196056</PMID>
  </reference>
  <reference>
    <citation>Yumuşak E, Örnek K. Comparison of Perioperative Ranibizumab Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery. J Ophthalmol. 2016;2016:7945619. doi: 10.1155/2016/7945619. Epub 2016 Jul 14.</citation>
    <PMID>27493795</PMID>
  </reference>
  <reference>
    <citation>Lim LL, Morrison JL, Constantinou M, Rogers S, Sandhu SS, Wickremasinghe SS, Kawasaki R, Al-Qureshi S. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month results. Clin Exp Ophthalmol. 2016 May;44(4):233-42. doi: 10.1111/ceo.12720. Epub 2016 Mar 29.</citation>
    <PMID>26871700</PMID>
  </reference>
  <reference>
    <citation>Schmier JK, Halpern MT, Covert DW, Matthews GP. Evaluation of costs for cystoid macular edema among patients after cataract surgery. Retina. 2007 Jun;27(5):621-8.</citation>
    <PMID>17558326</PMID>
  </reference>
  <reference>
    <citation>Hayashi K, Igarashi C, Hirata A, Hayashi H. Changes in diabetic macular oedema after phacoemulsification surgery. Eye (Lond). 2009 Feb;23(2):389-96. Epub 2007 Oct 26.</citation>
    <PMID>17962820</PMID>
  </reference>
  <reference>
    <citation>Hartnett ME, Tinkham N, Paynter L, Geisen P, Rosenberg P, Koch G, Cohen KL. Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol. 2009 Dec;148(6):895-901.e1. doi: 10.1016/j.ajo.2009.07.014. Epub 2009 Oct 17.</citation>
    <PMID>19837384</PMID>
  </reference>
  <reference>
    <citation>Ferguson VM, Spalton DJ. Continued breakdown of the blood aqueous barrier following cataract surgery. Br J Ophthalmol. 1992 Aug;76(8):453-6.</citation>
    <PMID>1390524</PMID>
  </reference>
  <reference>
    <citation>Dong N, Xu B, Wang B, Chu L, Tang X. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery. Biomed Res Int. 2015;2015:126984. doi: 10.1155/2015/126984. Epub 2015 Feb 25.</citation>
    <PMID>25811020</PMID>
  </reference>
  <reference>
    <citation>Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis. Br J Ophthalmol. 2006 Jun;90(6):697-701. Epub 2006 Mar 15.</citation>
    <PMID>16540489</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 5, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bay Area Retina Associates</investigator_affiliation>
    <investigator_full_name>Caesar Luo, MD, FACS</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

